Stockscreener 앱 받기
112.99
0.43%
0.48
시간 외 거래:
112.99
전일 마감가:
$112.51
열려 있는:
$110.73
하루 거래량:
571.68K
Relative Volume:
0.79
시가총액:
$5.23B
수익:
-
순이익/손실:
$-162.72M
주가수익비율:
-30.78
EPS:
-3.6714
순현금흐름:
$-144.89M
1주 성능:
+2.00%
1개월 성능:
+5.82%
6개월 성능:
+117.79%
1년 성능:
+973.03%
1일 변동 폭
$107.12
$115.08
1주일 범위
$107.12
$119.28
52주 변동 폭
$7.575
$120.31
Celcuity Inc Stock (CELC) Company Profile
명칭
Celcuity Inc
전화
763-392-0767
주소
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
112.99 | 5.21B | 0 | -162.72M | -144.89M | -3.6714 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 개시 | Wells Fargo | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | 개시 | Guggenheim | Buy |
| 2025-07-01 | 재개 | Stifel | Buy |
| 2024-07-22 | 개시 | Leerink Partners | Outperform |
| 2024-02-22 | 개시 | Stifel | Buy |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-08 | 개시 | Canaccord Genuity | Buy |
| 2021-09-07 | 개시 | Jefferies | Buy |
| 2021-07-29 | 개시 | Cowen | Outperform |
| 2021-07-27 | 개시 | Needham | Buy |
| 2021-01-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-11 | 재개 | Craig Hallum | Buy |
| 2018-11-20 | 개시 | H.C. Wainwright | Buy |
모두보기
Celcuity Inc 주식(CELC)의 최신 뉴스
Celcuity (CELC) price target increased by 11.17% to 108.57 - MSN
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call - The Manila Times
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and ... - Bluefield Daily Telegraph
Why (CELC) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - AOL.com
Needham & Company LLC Reiterates Buy Rating for Celcuity (NASDAQ:CELC) - MarketBeat
HighVista Strategies LLC Purchases New Position in Celcuity, Inc. $CELC - MarketBeat
49,281 Shares in Celcuity, Inc. $CELC Purchased by Granahan Investment Management LLC - MarketBeat
Celcuity publishes Phase 3 trial results in medical journal - Investing.com Nigeria
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Celcuity prices $248.7M debt, stock offerings - MSN
What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders - Yahoo Finance
90,000 Shares in Celcuity, Inc. $CELC Purchased by Boxer Capital Management LLC - MarketBeat
Apis Capital Advisors LLC Acquires New Holdings in Celcuity, Inc. $CELC - MarketBeat
The Bull Case For Celcuity (CELC) Could Change Following Strong VIKTORIA-1 Gedatolisib Phase 3 Data - simplywall.st
Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference - MarketBeat
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - The Motley Fool
Celcuity: Undervalued Pipeline with Differentiated Clinical Profile Supports Buy Rating - TipRanks
15,000 Shares in Celcuity, Inc. $CELC Purchased by Aristides Capital LLC - MarketBeat
Celcuity’s Gedatolisib Advances With Pivotal Data And FDA Priority Review - Sahm
Wolfe Research Maintains Outperform on Celcuity Inc (CELC) Mar 12, 2026 - Meyka
Celcuity stock maintained at Outperform by Wolfe on efficacy outlook - Investing.com South Africa
Celcuity Stock Pre-Market (-0.2%): Needham Raises Target on Strong Data Publication - Trefis
Buyback Watch: Can Celcuity Inc ride the EV waveEarnings Risk Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Is Celcuity (CELC) Pricing Reflecting Its Sharp Rally And DCF-Heavy Discount? - simplywall.st
Assessing Celcuity (CELC) Valuation After Strong Recent Returns And Optimistic Growth Forecasts - Sahm
CELC: Gedatolisib delivers record efficacy in breast cancer, with launch and global expansion plans advancing - TradingView
Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing - Yahoo Finance
Celcuity (CELC) surges 662% in 2025 on breast cancer treatment trial results - MSN
Needham Raises Price Target for Celcuity (CELC) to $122 | CELC S - GuruFocus
Celcuity (NASDAQ:CELC) Price Target Raised to $122.00 - MarketBeat
Needham raises Celcuity stock price target on priority review status By Investing.com - Investing.com Nigeria
Needham raises Celcuity stock price target on priority review status - Investing.com
Celcuity publishes Phase 3 trial results in medical journal By Investing.com - Investing.com Canada
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology - The Manila Times
Assessing Celcuity (CELC) Valuation As DCF Outlook Diverges Sharply From Narrative Fair Value - Yahoo Finance
Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference - MarketBeat
Buybacks Report: Should I set a stop loss on Celcuity IncDollar Strength & Breakout Confirmation Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (CELC) - Stock Traders Daily
Vanguard Group Inc. Raises Stock Position in Celcuity, Inc. $CELC - MarketBeat
Celcuity Inc (CELC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):